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bjectives We assessed the impact of vessel size on outcomes of stenting with biolimus-eluting
egradable polymer stent (BES) and sirolimus-eluting permanent polymer stent (SES) within a ran-
omized multicenter trial (LEADERS).
ackground Stenting of small vessels might be associated with higher rates of adverse events.
ethods “All-comer” patients (n  1,707) were randomized to BES and SES. Post-hoc–stratiﬁed
nalysis of angiographic and clinical outcomes at 9 months and 1 year, respectively, was performed
or vessels with reference diameter 2.75 mm versus 2.75 mm.
esults Of 1,707 patients, 429 patients in the BES group with 576 lesions and 434 patients in the SES
roup with 557 lesions had only small vessels treated (50.6% of the patient cohort). In patients with
mall vessels there was no signiﬁcant difference in overall major adverse cardiac events (MACE) rate
12.1% vs. 11.8%; p  0.89) or target lesion revascularization (TLR) rate (9.6% vs. 7.4%; p  0.26) be-
ween BES and SES. The MACE and TLR rates in the small-vessel patient population were higher than in
he large-vessel population. The TLR rate was 9.6% versus 2.6%, and MACE rate was 12.1% versus 7.1%
or small versus large vessels in the BES arm (TLR: hazard ratio [HR]  3.724, p  0.0013; MACE: HR 
.720, p  0.0412). In the SES arm, TLR was 7.4% versus 5.1%, and MACE was 11.8% versus 10.3% in
mall versus large vessels (TLR: HR  1.435, p  0.2594; MACE: HR  1.149, p  0.5546).
onclusions Prevalence of small vessel disease is high in an “all-comer” population with higher TLR
nd MACE rates. The BES and SES seem equivalent in treatment outcomes of small vessels in this
all-comer” patient population. (J Am Coll Cardiol Intv 2009;2:861–70) © 2009 by the American
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862he recently published “all-comers” European LEADERS
Biolimus-eluting stent with biodegradable polymer versus
irolimus-eluting stent with durable polymer for coronary
evascularization) trial showed that the biolimus-eluting
iodegradable polymer stent (BES) represents a safe and
oninferior alternative to sirolimus-eluting durable polymer
tent (SES) in the treatment of coronary artery disease (1).
iolimus is a highly lipophilic sirolimus analogue (2). It
nhibits the mammalian target of rapamycin and cell-cycle
ransition in smooth muscle cells with similar potency as
irolimus. It is eluted from a polylactic acid biodegradable
olymer solely applied on the abluminal surface. Unlike
aclitaxel-eluting stents (PES), BES has similar potency as
ES in the suppression of neoinitmal hyperplasia and
herefore late luminal loss (0.13 vs. 0.19 mm; p  0.34 at 9
onths). The amount of late luminal loss is usually inde-
endent of vessel size (3–8), and therefore a greater degree
of restenosis is observed in
smaller vessels owing to a re-
duced ability to accommodate
neointimal growth without caus-
ing hemodynamically significant
flow compromise (9,10). In the
RAVEL (Randomized Study
With the Sirolimus-Eluting Bx
Velocity Balloon-Expandable
Stent) study it was first demon-
strated that SES perform well in
small vessels with low restenosis
rates (11). At 6-month follow-
up, the restenosis rate in the
SES group was 0% versus 20%
to 35% in the different vessel-
size strata of the bare-metal
stents group. We hypothesized
that, given the non-inferior rate
of late loss in the BES arm of
he LEADERS trial, BES will perform equivalently in
mall vessels to SES, unlike PES.
ethods
evice description. The BES, as used in this study and
lready described in the preceding text, elutes a highly
ipophilic sirolimus analogue (2) (Fig. 1), which inhibits the
ammalian target of rapamycin and cell-cycle transition in
mooth muscle cells with similar potency as sirolimus. It is
luted from a polylactic acid biodegradable polymer applied
o the abluminal surface (Fig. 1). This fully biodegradable
olymer polylactic acid is metabolized to water and carbon
ioxide and promises to cause less long-term inflammatory
eaction. Full resorption occurs within 6 months. In the
EADERS trial the BES was found noninferior to the SES
bbreviations and
cronyms
ES  biolimus-eluting
tent(s)
ACE  major adverse
ardiac events
I  myocardial infarction
LD  minimal lumen
iameter
ES  paclitaxel-eluting
tent(s)
VD  reference vessel
iameter
ES  sirolimus eluting
tent(s)
LR  target lesion
evascularization
VR  target vessel
evascularizationn terms of major adverse cardiac events (MACE) at 9 ionths as well as in-stent percent diameter stenosis (p 
S) (1).
tudy population. The LEADERS trial was a multicenter
uropean non-inferiority trial comparing the safety and
fficacy of BES with SES in 1,707 “all-comers” patients.
atients over the age of 18 with chronic stable coronary
rtery disease or acute coronary syndromes including ST-
egment elevation myocardial infarction (MI) were eligible
f they had at least 1 lesion with 50% diameter stenosis
nd reference vessel diameter 2.25 to 3.5 mm. The aim was
or the patient population to reflect real world clinical
ractice, and thus no limits were set on the number or
omplexity of the lesions stented. The only exclusion criteria
ere: known allergy to acetylsalicylic acid, clopidogrel,
eparin, stainless steel, sirolimus, biolimus, or contrast material
hat cannot be pre-medicated; planned surgery within 6
onths of percutaneous coronary intervention unless the dual
nti-platelet therapy could be maintained throughout the
erisurgical period; pregnancy or participation in another trial
efore reaching the primary end point; and lastly, inability to
ive informed consent. The study complied with the Declara-
ion of Helsinki and was approved by all institutional ethics
ommittees. All patients provided written informed consent
or participation in the trial.
andomization and procedures. Randomization was done
entrally after diagnostic cardiac catheterization and before
ercutaneous coronary intervention (PCI) by use of a
elephone allocation service (Limburgia telefonische Ant-
oord Service, Rotterdam, the Netherlands). The allocation
equence was computer-generated, stratified according to
enter, and blocked with block sizes of 8 and 16, which
aried randomly. We randomly allocated patients on a 1:1
asis to treatment with a BES (Biomatrix Flex, Biosensors,
nc., Newport Beach, California) or an SES (Cypher Select,
ordis, Miami Lakes, Florida) and to active angiographic
ollow-up at 9 months or clinical follow-up only on a 1:3
asis with a factorial design.
The BES were available in diameters of 2.25, 2.5, 3.0,
nd 3.5 mm and in lengths of 8, 11, 14, 18, 24, and 28 mm.
he SES were available in diameters of 2.25, 2.5, 2.75, 3.0,
nd 3.5 mm and in lengths of 8, 13, 18, 23, 28, and 33 mm.
e performed balloon angioplasty and stent implantation
ccording to standard technique, and direct stenting was
llowed. No mixture of drug-eluting stents was permitted
ithin a given patient, unless the operator was unable to
nsert the study stent, in which case crossover to another
evice of the operator’s choice was possible. Before or at the
ime of the procedure, patients were given at least 75 mg of
cetylsalicylic acid, 300 to 600 mg loading dose of clopi-
ogrel, and unfractionated heparin at a dose at least 70
U/kg. After the procedure, all patients were advised to take
spirin indefinitely and clopidogrel for at least 12 months.
n case of intercurrent revascularization procedures requir-
ng stent implantation, treating cardiologists were encour-
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863ged to use the study stent. For other details we refer to the
rimary end point article (1).
tudy end points. Adverse events were assessed in the
ospital and at 1, 6, 9, and 12 months. An independent
linical events committee unaware of the patient’s treatment
ssignments adjudicated all end points. One in four patients
as asked to return for angiographic follow-up at 9 months.
efinitions of all end points are provided elsewhere (1).
riefly, the pre-specified primary end point was the com-
osite of cardiac death, MI, and clinically indicated target
essel revascularization (TVR) within 9 months. Secondary
nd points were any target lesion revascularization (TLR)
both clinically and nonclinically indicated), which was
efined as repeat revascularization due to a stenosis within
he stent or within a 5-mm border proximal or distal to the
tent; any TVR, cardiac death, death from any cause, MI,
tent thrombosis (defined according to the Academic Re-
earch Consortium) (12); device success (defined as achieve-
ent of a final residual diameter stenosis of 50% during
he initial procedure); and lesion success (achievement of
50% stenosis with any approach for PCI).
The pre-specified principal outcome of the angiographic
ubstudy was in-stent percent diameter stenosis. Secondary
ngiographic outcomes were in-segment percent diameter
tenosis, minimal lumen diameter (MLD), late lumen loss,
nd binary restenosis. We obtained angiographic measure-
ents within the stented segment (in-stent) and over the
ntire segment consisting of the stent and 5-mm proximal
nd distal margins (in-segment). We defined percent diam-
ter stenosis as: ([reference vessel diameter  MLD]/
Figure 1. Structure of Biolimus and Scanning Electron Micrograph of the Beference vessel diameter)  100%; late lumen loss as the iifference between MLD after the procedure and MLD at
ollow-up; and binary restenosis as percentage diameter
tenosis of 50% or greater in the target lesion.
Independent study monitors (D-Target, Montagny-pres-
verdon, Switzerland) verified all case reports from data
n-site. Data were stored in a database (KIKA Medical,
aris, France), which was maintained by a contract research
rganization (Cardialysis, Rotterdam, the Netherlands) in
ollaboration with an academic clinical trials unit (CTU
ern, Bern University Hospital, Bern, Switzerland). Clini-
al follow-up was done at 1, 6, 9, and 12 months. The
perators were by necessity aware of the assigned study stent
uring PCI and angiographic follow-up, but patients and
taff involved in follow-up assessment were blinded to the
llocated stent type. Angiographies were centrally assessed
t 1 angiographic core laboratory (Cardialysis) with asses-
ors unaware of the allocated stent.
tatistical analysis. A stratified post-hoc analysis of clinical
nd angiographic outcomes, which was specified after com-
letion of patient recruitment, was performed according to
essel size. Methodology similar to the previously published
IRTAX (Sirolimus-Eluting Versus Paclitaxel-Eluting
tents for Coronary Revascularization) trial was used (9).
uantitative coronary angiography served to determine the
eference vessel diameter (RVD). Patients who underwent
tent implantation in lesions with an RVD 2.75 mm were
ategorized as having undergone treatment of small vessels.
onversely, patients who underwent stent implantation in
esions with RVD 2.75 mm were classified as having had
reatment of large vessels. Patients with stent implantations
s Biodegradable Polymer Stentn both small and large vessels were classified as “mixed”. All
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864andomized patients were included in the analysis of pri-
ary and secondary clinical end points in the groups that
hey were originally assigned to (intention-to-treat analysis).
nalyses of the angiographic substudy were restricted to
esions from patients who attended follow-up angiography.
ngiographic outcomes were analyzed with SAS version 8
roc Mixed (SAS Institute, Cary, North Carolina) for
ontinuous and Proc Genmod for binominal outcomes,
aking into account the within-patient correlation structure
f these data. We used a Cox proportional hazards model to
ompare clinical outcomes between the groups. All analyses
ere performed with SAS version 8.02 by a dedicated
tatistician. All p values and confidence intervals were
-sided.
esults
aseline clinical, angiographic, and procedural data. A total
f 1,707 patients with 2,467 lesions were randomly assigned
o treatment with either BES (857 patients, 1,254 lesions)
r SES (850 patients, 1,213 lesions). Four hundred twenty-
ine patients in the BES group with 576 lesions and 434
atients in the SES group with 557 lesions had only small
essels treated (863 of 1,707 [50.6%] of the entire patient
opulation); 267 patients in the BES arm with 309
esions and 272 patients in the SES arm with 311 lesions
ad only large vessels treated (RVD 2.75); and 154
atients in the BES group with 362 lesions and 133
atients with 334 lesions in the SES group had “mixed”
Figure 2. Study Flow Chartisease (Fig. 2). lBaseline clinical and angiographic characteristics are
ummarized in Tables 1 and 2. There were no significant
ifferences in the numbers of patients with diabetes, hyper-
ension, hypercholesterolemia, smoking history, prior his-
ory of MI, stroke, or peripheral vascular disease between
he SES and BES groups. These patient characteristics
iffered, however, when compared for vessel size. There was
higher proportion of women with small vessels (29% vs.
5% overall; p 0.001), whereas no significant difference in
he numbers of diabetic patients across vessel sizes was
ound. Smokers were more frequently found in the large
essel group (p  0.001), whereas patients with small vessel
isease had a higher frequency of previous MIs (p  0.007)
nd past history of PCI (p  0.001). A high proportion of
atients in the entire cohort had presented with acute
oronary syndromes (between 51% and 61%) and 13% to
1% of the cases were ST-segment elevation MIs. Lastly,
atients with mixed vessel disease had a higher proportion
f multivessel disease (p  0.001).
Mean reference vessel diameters in the BES and SES
roup were 2.21  0.34 mm and 2.24  0.33 mm for small
essels, respectively, 3.21  0.47 mm and 3.18  0.37 mm
or large vessels, and 2.69  0.57 mm and 2.66  0.59 mm
or mixed lesions (Table 1). The lesion length did not differ
etween the 2 treatment groups but differed slightly over the
ange of 12 to 16 mm between vessel sizes. Percent diameter
tenosis was 63  18% in small vessels in both treatment
rms, 66  18% in large vessels treated with BES, 69 
8% in large vessels treated with SES, 62  18% in the
ixed vessels treated with BES, and 61 18% in the mixed
essels treated with SES. The MLD amounted to 0.80 and
.84 mm in small vessels treated with BES and SES and
.01 and 1.07 mm in large vessels treated with BES and
ES, respectively.
Procedural results are shown in Table 2. Post-stenting
LD in small vessels treated with BES and SES was 2.09 
.35 mm and 2.13 0.35 mm, respectively (pNS); it was
.76  0.41 mm and 2.67  0.38 mm in large vessels
reated with BES and SES, respectively. There were no
ignificant differences in acute gain after stenting with BES
r SES, the acute gain being 1.29  0.45 mm for small
essels, 1.74  0.62 mm for large vessels treated with BES,
nd 1.59  0.59 mm for large vessels treated with SES.
his translated also in equivalent diameter stenosis after
CI in both stent groups.
ngiographic results. Angiographic follow-up at 9 months
ere obtained in 168 patient in the BES group and 167
atients in the SES group (Table 2). One hundred nine
mall vessel lesions, 62 large vessel lesions, and 82 mixed
essel lesions were evaluated angiographically at 9 months in
he group treated with BES. One hundred fourteen small
essel lesions, 58 large vessel lesions, and 59 mixed lesions
ere evaluated angiographically in the SES group. In small,arge, and mixed vessels there was no significant difference
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865n late luminal loss, MLD, percent diameter stenosis, or
inary restenosis between BES and SES groups. In small
essels late loss was 0.17  0.47 mm in the BES group and
.22  0.51 mm in the SES group (p  NS). Correspond-
ng percent diameter stenosis was 24.9 20.7% and 23.8
1.3% in the BES and SES stent groups, respectively. In the
arge lesion population, in-stent late luminal loss was 0.14
.51 in the BES arm and 0.05  0.37 in the SES group
p  NS). The percent diameter stenosis in the large vessel
roup was 18.2  14.6% in the BES group and 19.2 
4.5% in the SES group (p  NS). Late loss, percent
iameter stenosis, and binary in-stent restenosis were lower
n the “mixed” lesion group treated with BES compared
ith SES.
linical outcomes. Clinical events at 1-year follow-up strat-
fied by vessel size are listed in Table 3 and summarized in
igures 3 and 4. Vessel size seemed to influence the TLR
ates in both SES and BES groups. Within the BES
reatment arm TLR rate was 9.6% in the small vessel group
41 events) versus 2.6% in the large vessel group (7 events).
ithin the SES treatment arm TLR rate was 7.4% in the
mall vessel group (32 events) versus 5.1% in the large vessel
Table 1. Baseline Clinical and Angiographic Characteristics for Small, Larg
BES, Small SES, Small BES
Patient demographic data
Number of patients 429 434
Age 65 yrs 225 (52) 209 (48) 12
Male 295 (69) 314 (72) 21
Diabetes 104 (24) 105 (24) 6
Hypertension 315 (73) 319 (74) 19
Hyperlipidemia 291 (68) 299 (69) 17
Current smoking 85 (20) 96 (22) 7
Previous MI 151 (35) 146 (34) 6
Previous PCI 184 (43) 180 (42) 7
Previous stroke 24 (6) 16 (4)
Previous PVD 39 (9) 35 (8) 1
Multivessel disease 83 (19) 58 (13) 2
Clinical presentation
Stable angina 160 (37) 156 (36) 7
Acute coronary syndromes 224 (52) 233 (54) 15
Unstable angina 99 (23) 92 (21) 5
STEMI 54 (13) 61 (14) 5
Non-STEMI 71 (17) 80 (18) 4
Angiographic parameters
Number of lesions 576 557
Lesion length 15  13 14  11 17
Reference vessel diameter 2.21  0.34 2.24  0.33 3.21
MLD 0.80  0.40 0.84  0.43 1.01
% diameter stenosis 63  18 63  18 69
Values are n, n (%), andmean SD. *The p value is given for the difference among the 3 groups (sm
permanent polymer stent (SES). †Tested: equal distribution in the 3 groups. ‡Tested: equal mean i
MImyocardial infarction; MLDminimal lumen diameter; PCI percutaneous coronary interroup (14 events). There were no differences in the overall cate of MACE or TLR/TVR in patients with small vessels
nd large vessels treated with BES versus SES stents. There
as no significant difference in overall MACE rate between
ES- and SES-treated patients with “mixed” vessel disease,
lthough rates of overall percutaneous TLR (7 [4.5%]
atients vs. 15 [11.3%] patients; p  0.037) were lower.
ests for interaction between treatment and vessel size
eached statistical significance for TLR and TVR rates in
he mixed disease group.
There were 13 definite stent thrombosis events in small
essels in the BES arm (3.0%) and 9 definite stent throm-
osis events in the SES arm (2.1%) (p  0.38).
iscussion
e present here a novel stent technology now commercially
vailable in Europe that combines the biodegradable poly-
er technology with solely abluminal elution of biolimus
nd performs well in complex lesions such as small vessels in
n “all-comer” patient population. The main finding of this
ubstudy of the LEADERS multicenter randomized trial
ocusing on the effect of vessel size on angiographic and
“Mixed” Vessel Groups
e SES, Large BES, Mixed SES, Mixed p Value*
272 154 133 †
134 (49) 78 (51) 73 (55) 0.44
207 (76) 125 (81) 105 (79) 0.001
56 (21) 51 (33) 29 (22) 0.18
205 (75) 117 (76) 88 (66) 0.74
177 (65) 95 (62) 101 (76) 0.27
82 (30) 41 (27) 33 (25) 0.002
84 (31) 59 (38) 46 (35) 0.007
88 (32) 48 (31) 44 (33) 0.001
6 (2) 9 (6) 6 (4.5) 0.06
19 (7) 18 (12) 9 (7) 0.12
22 (8) 103 (67) 96 (72) 0.001
78 (29) 55 (36) 53 (40) 0.03
166 (61) 87 (56.5) 68 (51) 0.042
61 (22) 33 (21) 27 (20)
56 (21) 22 (14) 18 (13.5)
49 (18) 32 (21) 23 (17)
311 363 334 ‡
16  12 14  10 13  9 0.001
7 3.18  0.37 2.69  0.57 2.66  0.59 0.001
3 1.08  0.58 1.02  0.48 1.05  0.53 0.001
66  18 62  17 61  17 0.001
, andmixed) rather than biolimus-eluting degradable polymer stent (BES) versus sirolimus-eluting
groups.
; PVD peripheral vascular disease; STEMI ST-segment elevation myocardial infarction.e, and
, Larg
267
5 (47)
7 (81)
3 (24)
3 (72)
0 (64)
6 (29)
4 (24)
7 (29)
7 (3)
3 (5)
2 (8)
9 (30)
6 (58)
8 (22)
6 (21)
2 (16)
309
 11
 0.4
 0.6
 18
all, large
n the 3linical outcomes is that BES seems noninferior to the
“
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866gold standard” SES in small vessels. To our knowledge this
s the first report of another drug-eluting stent being
oninferior to SES in the setting of small vessel disease.
ngiographic outcomes at 9-month follow-up in a subset of
atients show equivalent late luminal loss, percent diameter
tenosis, and binary restenosis rates, which translate into
imilar rates of MACE and TLR at 1 year in both stent
reatment groups in small vessel disease. This equivalent
erformance is achieved in a complex “all-comer” patient
opulation that reflects “real world” clinical practice. These
esults in small vessel disease are unlike those reported in
rials to date comparing SES and PES, where SES has
hown a consistent advantage over PES in both angio-
raphic and clinical outcomes (13–16).
Another important finding of our study is that the
revalence of small vessel lesions (defined as reference
iameter 2.75 mm) is high (50.6%) in real world clinical
ractice, and the overall rate of MACE and TLR in small
essel lesions across stent types are higher than for large
Table 2. Baseline Angiographic Characteristics, Procedural Outcomes, and
BES, Small SES, Small BES
Number at initial procedure
(at 9-month follow-up)
561 (105) 539 (114) 308
In-stent
Reference vessel diameter
After procedure 2.46 (0.36) 2.48 (0.35) 3.24
9-month follow-up 2.55 (0.37) 2.45 (0.39) 3.25
MLD
After procedure 2.09 (0.35) 2.13 (0.35) 2.76
9-month follow-up 1.91 (0.59) 1.87 (0.62) 2.65
Acute gain 1.29 (0.46) 1.30 (0.45) 1,74
Late loss 0.17 (0.47) 0.22 (0.51) 0.14
% diameter stenosis
After procedure 14.8 (8.4) 14.1 (7.6) 14.6
9-month follow-up 24.9 (20.7) 23.8 (21.3) 18.2
Binary restenosis rate (%) 10.1 7.9
In-segment
Reference vessel diameter
After procedure 2.37 (0.38) 2.39 (0.38) 3.14
9-month follow-up 2.50 (0.38) 2.37 (0.40) 3.16
MLD
After procedure 1.78 (0.36) 1.84 (0.37) 2.48
9-month follow-up 1.73 (0.55) 1.65 (0.56) 2.42
Acute gain 0.99 (0.48) 1.00 (0.47) 1.45
Late loss 0.09 (0.44) 0.19 (0.48) 0.10
% diameter stenosis
After procedure 24.4 (10.1) 23.3 (9.3) 21.0
9-month follow-up 30.6 (19.2) 30.6 (19.7) 23.3
Binary restenosis rate (%) 12.8 9.7
Values are mean (SD), unless otherwise indicated.
Abbreviations as in Table 1.essel lesions (Online Figures). This latter finding is at pariance with recent findings of the BASKET (Basel Stent
ost-Effectiveness Trial) 3-year follow-up, where within
he drug-eluting stent-treated group there seemed to be no
ifference in the MACE and TLR rates between small and
arge vessels (17). The increased event rate in the large stent
roup seemed to be a late rather than early phenomenon,
ith the curve diverging after 6 to 9 months, a phenomenon
hat might have been missed in the present study with only
-year clinical follow-up. Conversely, failure to detect ear-
ier higher event rates in the small vessel group in the
ASKET study might have been due to the lower
umber of patients (187 patients with small vessels
reated with DES compared with 863 patients in the
resent study).
The SES (Cypher Select) uses a poly-n-butyl metha-
rylate durable polymer technology for drug elution that has
een shown to cause inflammation and fibrin deposi-
ion as well as endothelial dysfunction and delayed endo-
helialization (18). Poly-n-butyl methacrylate is hydro-
ographic Follow-Up Results at 9 Months
SES, Large BES, Mixed SES, Mixed
p Value
Interaction
309 (58) 360 (82) 326 (59)
3.16 (0.40) 2.79 (0.52) 2.79 (0.52) 0.0192
3.21 (0.44) 2.84 (0.49) 2.81 (0.51) 0.7792
2.67 (0.38) 2.36 (0.51) 2.38 (0.50 0.0033
2.60 (0.59) 2.08 (0.51) 1.83 (0.62) 0.209
1.60 (0.59) 1.34 (0.55) 1.32 (0.53) 0.0169
0.05 (0.37) 0.06 (0.40) 0.25 (0.56) 0.047
15.2 (7.0) 15.0 (9.7) 14.7 (9.1) 0.3955
19.2 (14.5) 17.8 (13.7) 26.4 (20.0) 0.0236
3.4 1.2 15.3 0.0144
3.06 (0.46) 2.69 (0.55) 2.71 (0.56) 0.0723
3.13 (0.46) 2.78 (0.52) 2.76 (0.52) 0.4379
2.44 (0.43) 2.07 (0.52) 2.07 (0.52) 0.0845
2.35 (0.56) 2.08 (0.51) 1.83 (0.62) 0.1293
1.36 (0.63) 1.04 (0.56) 1.02 (0.53) 0.2238
0.04 (0.33) 0.04 (0.42) 0.19 (0.51) 0.079
20.2 (8.8) 22.8 (10.6) 23.3 (10.5) 0.236
24.8 (14.7) 25.2 (12.7) 33.3 (18.7) 0.1105
5.2 1.2 18.6 0.0052Angi
, Large
(62)
(0.42)
(0.33)
(0.41)
(0.53)
(0.62)
(0.51)
(7.5)
(14.6)
3.2
(0.45)
(0.36)
(0.46)
(0.50)
(0.66)
(0.49)
(8.6)
(14.0)
3.2hobic and causes monocytes to adhere to its surface and
Table 3. Clinical Outcomes at 1-Year Follow-Up
BES, Small
(n  429)
SES, Small
(n  434) HR (95% CI)
p
Value
BES, Large
(n  267)
SES, Large
(n  272) HR (95% CI)
p
Value
BES, Mixed
(n  154)
SES, Mixed
(n  133) HR (95% CI)
p
Value
p Value
Interaction
Death 12 (2.8) 10 (2.3) 1.21 (0.52–2.8) 0.65 10 (3.7) 12 (4.4) 0.85 (0.37–1.97) 0.71 4 (2.6) 5 (3.8) 0.68 (0.18–2.55) 0.57 0.73
Cardiac death 10 (2.3) 8 (1.8) 1.26 (0.50–3.20) 0.62 6 (2.2) 9 (3.3) 0.68 (0.24–1.91) 0.47 1 (0.6) 5 (3.8) 0.17 (0.02–1.47) 0.11 0.16
MI 24 (5.6) 20 (4.6) 1.21 (0.67–2.19) 0.52 10 (3.7) 11 (4.0) 0.92 (0.39–2.17) 0.85 16 (10.4) 7 (5.3) 2.02 (0.83–4.92) 0.12 0.43
All TLR 41 (9.6) 32 (7.4) 1.31 (0.82–2.08) 0.26 7 (2.6) 14 (5.1) 0.50 (0.20–1.25) 0.14 8 (5.2) 15 (11.3) 0.44 (0.19–1.04) 0.06 0.03
TLR percutaneous 40 (9.3) 31 (7.1) 1.32 (0.83–2.11) 0.25 5 (1.9) 12 (4.4) 0.42 (0.15–1.20) 0.10 7 (4.5) 15 (11.3) 0.39 (0.16–0.95) 0.037 0.014
TLR surgical 5 (1.2) 4 (0.9) 1.26 (0.34–4.68) 0.73 2 (0.7) 2 (0.7) 1.02 (0.14–7.23) 0.99 1 (0.6) 1 (0.8) 0.84 (0.05–13.46) 0.90 0.96
Clinically justiﬁed TLR 34 (7.9) 26 (6.0) 1.33 (0.80–2.21) 0.28 5 (1.9) 11 (4.0) 0.46 (0.16–1.32) 0.15 5 (3.2) 10 (97.5) 0.42 (0.14–1.23) 0.11 0.05
Clininally justiﬁed
TLR percutaneous
33 (7.7) 25 (5.8) 1.34 (0.80–2.26) 0.27 4 (1.5) 10 (3.7) 0.40 (0.13–1.29) 0.13 5 (3.2) 10.75 0.42 (0.14–1.23) 0.11 0.041
Clininally justiﬁed
TLR surgical
4 (0.9) 3 (0.7) 1.34 (0.30–6.00) 0.70 1 (0.4) 1 (0.4) 1.02 (0.06–16.33) 0.99 — — 0.99
All TVR 46 (10.7) 43 (9.9) 1.08 (0.72–1.64) 0.7 10 (3.7) 21 (7.7) 0.48 (0.22–1.01) 0.054 10 (6.5) 18 (13.5) 0.45 (0.21–0.99) 0.046 0.048
TVR percutaneous 44 (10.3) 39 (9.0) 1.15 (0.75–1.77) 0.53 6 (2.2) 17 (6.3) 0.35 (0.14–0.90) 0.029 9 (5.8) 18 (13.5) 0.41 (0.18–0.91) 0.029 0.012
TVR surgical 6 (1.4) 7 (1.6) 0.86 (0.29–2.56) 0.79 4 (1.5) 4 (1.5) 1.02 (0.25–4.07) 0.98 1 (0.6) 1 (0.8) 0.84 (0.05–13.46) 0.90 0.98
Clininally justiﬁed TVR 36 (8.4) 32 (7.4) 1.14 (0.71–1.83) 0.59 7 (2.6) 14 (5.1) 0.50 (0.20–1.25) 0.14 6 (3.9) 12 (9.0) 0.42 (0.16–1.11) 0.08 0.08
Clininally justiﬁed
TVR percutaneous
35 (8.2) 31 (7.1) 1.15 (0.71–1.86) 0.58 5 (1.9) 12 (4.4) 0.42 (0.15–1.19) 0.10 6 (3.9) 12 (9.0) 0.42 (0.16–1.11) 0.08 0.06
Clininally justiﬁed
TVR surgical
4 (0.9) 3 (0.7) 1.34 (0.30–6.00) 0.70 2 (0.7) 2 (0.7) 1.02 (0.14–7.22) 0.99 — 1 (0.8) 0.42
Stent thrombosis 19 (4.4) 12 (2.8) 1.61 (0.78–3.32) 0.20 6 (2.2) 8 (2.9) 0.76 (0.26–2.19) 0.61 5 (3.2) 6 (4.5) 0.72 (0.22–2.34) 0.58 0.36
Deﬁnite stent
thrombosis
13 (3.0) 9 (2.1) 1.47 (0.63–3.43) 0.38 1 (0.4) 4 (1.5) 0.25 (0.03–2.27) 0.22 3 (1.9) 4 (3.0) 0.65 (0.14–2.88) 0.57 0.22
Possible stent
thrombosis
2 (0.5) 3 (0.7) 0.67 (0.11–4.02) 0.66 4 (1.5) 3 (1.1) 1.36 (0.30–6.09) 0.69 1 (0.6) 3 (2.3) 0.28 (0.03–2.73) 0.28 0.49
Probable stent
thrombosis
5 (1.2) 1 (0.2) 5.05 (0.59–43.24) 0.14 1 (0.4) 1 (0.4) 1.02 (0.06–16.36) 0.99 — 1 (0.6) 0.53
MACE 52 (12.1) 51 (11.8) 1.03 (0.70–1.51) 0.89 19 (7.1) 28 (10.3) 0.68 (0.38–1.22) 0.20 18 (11.7) 19 (14.3) 0.83 (0.44–1.58) 0.57 0.50
Target vessel failure 58 (13.5) 57 (13.1) 1.03 (0.71–1.48) 0.88 17 (6.4) 30 (11.0) 0.57 (0.31–1.03) 0.06 18 (11.7) 24 (18) 0.63 (0.34–1.17) 0.14 0.16
CIconfidence interval; HR hazard ratio; MACEmajor adverse cardiac events; TLR target lesion revascularization; TVR target vessel revascularization; other abbreviations as in Table1.
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868roduce cytokines such as monocyte chemotactic protein-1,
lasminogen activator inhibitor-1, and tissue factor (19).
ersistence of this pro-inflammatory polymer is hypothe-
ized to be a potential major contributor to late stent
hrombosis events. The BES in the present study uses,
nlike SES, a biodegradable polymer made of polylactic
cid, which completely disintegrates to water and carbon
ioxide within 6 months. Therefore, it holds promise of a
ower rate of late stent thrombosis or need for dual anti-
latelet inhibition in the long term as well as equivalent
erformance in terms of efficacy in the short term. The drug
s eluted on the abluminal surface and therefore might be
ypothetically less likely to cause delayed endothelialization,
hile still preventing in-stent restenosis.
We noted a higher number of stent thrombosis cases than
n on-label clinical trials, particularly in small vessels in both
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Figure 3. Kaplan-Meier Curves for Overall MACE Rate at 1 Year
Kaplan-Meier curves for overall major adverse cardiac events (MACE) rate at 1ES- and SES-treated groups of patients. Yet, the rate of vtent thrombosis corresponds well to other all-comer trials
uch as SYNTAX (Synergy Between PCI With Taxus and
ardiac Surgery) (20). It might also be explained by a
elatively high percentage of patients with acute coronary
yndromes, including up to 21% with ST-segment elevation
I, because similar rates of stent thrombosis have been
eported in TRITON–TIMI 38 (A Comparison of CS-747
nd Clopidogrel in Acute Coronary Syndrome Subjects who
re to Undergo Percutaneous Coronary Intervention–
hrombolysis In Myocardial Infarction 38) and HORIZON-
MI (Harmonizing Outcomes With Revascularization and
tents in Acute Myocardial Infarction) trials (21,22). There
eems to be overall similar rates of definite stent thrombosis
n small, large, and “mixed” vessel groups. Longer-term
ollow-up will determine whether the biodegradable poly-
er adds any advantage over a durable polymer in terms of
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869Lastly, there seems to be an advantage of treatment with
ES in patients with “mixed” lesions and multivessel
isease. This difference in angiographic outcomes (late loss)
nd trend to a significant difference in TLR and TVR in
atients with “mixed” disease must be explored further.
lthough late loss has been established as a discriminating
actor in stent performance (3–5), it remains uncertain
hether this translates into differences in long-term clinical
utcomes. The interpretation of this result in this complex
roup with “mixed” lesions is difficult; nevertheless, given
he prevalence of “mixed” lesion populations in our clinical
ractice, it is noteworthy.
tudy limitations. The study suffers from the usual limita-
ions of post hoc analyses and, for some subgroup analyses,
ight lack sufficient power to detect superiority of 1
reatment over the other. Some of the key differences in
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Figure 4. Kaplan-Meier Curves for TLR Rates at 1 Year
Kaplan-Meier curves for target lesion revascularization (TLR) rates at 1 year. (Autcomes such as late stent thrombosis in a degradable mersus permanent polymer stent might emerge at long-term
ollow-up.
onclusions
essel size has been an important predictor of in-stent
estenosis and clinical events. The SES have been thus far
uperior to PES and bare-metal stents in treatment of small
essels. We demonstrate for the first time the non-
nferiority of BES to SES in angiographic late loss and
ercutaneous TLR rates.
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